找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller Book 2016Latest edition Springer International Publishing Switzerlan

[復(fù)制鏈接]
樓主: 厭倦了我
41#
發(fā)表于 2025-3-28 16:02:43 | 只看該作者
Margareta Stefanovic,Michael G. Safonovand that “drug therapy varies widely among individuals” [.]. These two statements set the stage for the discipline of clinical pharmacology (CP) which pursues two main goals: (1) an empirical description of conditions under which drug actions vary in humans and (2) to determine and understand the mo
42#
發(fā)表于 2025-3-28 20:33:58 | 只看該作者
Margareta Stefanovic,Michael G. Safonoves, most notably infections, have extremely satisfying therapeutic success rates, and many serious diseases like diabetes mellitus or some forms of cancer have become chronic, stable diseases and do not lead to extreme shortages of life years any longer. Prime examples for success stories in drug de
43#
發(fā)表于 2025-3-29 00:38:09 | 只看該作者
44#
發(fā)表于 2025-3-29 04:27:29 | 只看該作者
45#
發(fā)表于 2025-3-29 09:45:47 | 只看該作者
46#
發(fā)表于 2025-3-29 14:01:19 | 只看該作者
Ken Chan,Clive Fencott,Barry Hebbronessively establish their safety and ultimately their efficacy. Disasters occur only rarely during phase I trials, which have a remarkable safety record. In 2006, a contract research organization was conducting the first human testing of TGN1412 an immunomodulatory anti-CD28 monoclonal antibody. All
47#
發(fā)表于 2025-3-29 19:36:42 | 只看該作者
48#
發(fā)表于 2025-3-29 20:30:31 | 只看該作者
49#
發(fā)表于 2025-3-30 03:06:15 | 只看該作者
50#
發(fā)表于 2025-3-30 07:34:57 | 只看該作者
Legal Aspects of Safety Critical Systemse the number of compounds where the pharmacokinetics observed at a microdose compared to a therapeutic dose has grown steadily. Based upon the most up-to-date review at the time of writing (2013, reference Lappin et al., Expert Opin Drug Metab Toxicol 9(7):817–834, 2013), there are 35 compounds wher
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 19:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
始兴县| 宁安市| 开封县| 城固县| 吉林省| 汝城县| 抚远县| 若羌县| 辽阳县| 望奎县| 余江县| 紫云| 丹寨县| 阜宁县| 开远市| 西林县| 文水县| 察雅县| 九江县| 罗田县| 沙湾县| 文昌市| 邢台县| 镇江市| 张家港市| 玛曲县| 永靖县| 中牟县| 平果县| 华蓥市| 应城市| 图木舒克市| 靖边县| 石城县| 信丰县| 闵行区| 丰台区| 常熟市| 湖南省| 乃东县| 富顺县|